Lupin partners with Sandoz for biosimilar ranibizumab commercialization

Lupin Limited has partnered with Sandoz for commercialization of its biosimilar ranibizumab. Sandoz will manage commercialization in the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia, with Lupin handling manufacturing and regulatory submissions. Sandoz will also acquire sole commercialization rights in Canada.